We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Supreme Court will likely have to revisit the practice of reverse payments — brand drugmakers paying generic drugmakers to delay generic competition — even after rejecting the FTC’s appeal to review an antitrust case on the matter, as a similar case may come up for review, a legal expert told WDL.